University of Dayton

eCommons
Graduate Theses and Dissertations

Theses and Dissertations

1998

The suppressive effect of pyocyanin on the humoral immune
response of mice
Angela Maria Gallo
University of Dayton

Follow this and additional works at: https://ecommons.udayton.edu/graduate_theses

Recommended Citation
Gallo, Angela Maria, "The suppressive effect of pyocyanin on the humoral immune response of mice"
(1998). Graduate Theses and Dissertations. 2808.
https://ecommons.udayton.edu/graduate_theses/2808

This Thesis is brought to you for free and open access by the Theses and Dissertations at eCommons. It has been
accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of eCommons. For
more information, please contact mschlangen1@udayton.edu, ecommons@udayton.edu.

THE SUPPRESSIVE EFFECT OF PYOCYANIN ON THE HUMORAL
IMMUNE RESPONSE OF MICE

Thesis
Submitted to
The College o f Arts and Science o f the
UNIVERSITY OF D A Y T O N

In Partial Fulfillment o f the Requirements for
The Degree
Master o f Science in B iology

By
Angela Maria Gallo

UNIVERSITY O F D A Y T O N
Dayton, Ohio
July 1998

UNIVERSITY OF DAYTON ROESCH LIBRARY

Approved by:

T-------r»--------------------------Robert J. Kearns, Ph.D

Major Advisor

Carl F. Friese, Ph.D.
Committee Member

Shirley J. Wright, i’li. D

Committee Member

John

Ph.D.

Chairman, Biology Department

ABSTR AC T

T H E S U P P R E S S IV E E F F E C T O F P Y O C Y A N IN O N T H E H U M O R A L
IM M U N E R E S P O N S E O F M IC E

Name: Angela Maria Gallo
University of Dayton, 1998
Major Advisor: Dr. Robert J. Kearns

Controlling the development or progression of disease within a host involves the
activity of both humoral and cell-mediated immunity. This includes the recruitment of cells
involved in antigen processing and presentation as well as those which promote the
secretion of cytokines and immunoglobulins. Pseudomonas aeruginosa is a gram negative,
opportunistic bacteria implicated in the morbidity and mortality of immunocompromised
individuals such as those with cystic fibrosis, cancer, and bums. This bacteria produces a
variety of metabolites, some of which have been characterized as toxic in hosts. Phenazine
pigments, which are secondary metabolites unique to Pseudomonas, have not been well
characterized in terms of their toxicity and potential to contribute to virulence of infections.
Pyocyanin, a low molecular weight phenazine pigment has previously been found to
interfere with mitogen stimulated lymphocyte blastogenesis as well as inhibit the secretion
of IL-2, a cytokine required for the proliferation of T-lymphocytes. However, the effects
of pyocyanin on the humoral immune system or cytokines potentially involved in the
induction of humoral immunity have not been well characterized.
Pyocyanin was isolated and purified from phenazine methosulfate (PMS). The
purification and structural analysis was checked by proton NMR and spectrophotometric
analysis. Initial studies on mice treated with 1.0 /zg, 10.0 /^g, and 100.0 /zg pyocyanin
revealed that pyocyanin at a 1.0 pg concentration injected intravenously into the tail veins
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of mice resulted in significant suppression (74% reduction) of plaque forming units (PFUs)
as measured by the hemolytic plaque assay. Trypan blue exclusion confirmed that the
decrease in PFUs was not due to a decrease in cell viability, as the percent of viable cells
remained above 87%. This indicated that the pigment, when administered at the same time
as sheep red blood cells (SRBC), had a suppressive effect on the ability of the animal to
mount an antibody response to SRBC. Pyocyanin (1.0 /^g) was then injected prior to, at
the same time as, and subsequent to SRBCs. The greatest suppression in PFUs occurred
when pyocyanin was injected 12h prior and 12 h subsequent to injection with SRBC, with
a percent reduction in PFUs of 83% and 79% respectively. These values were statistically
different from the number of PFUs obtained when pyocyanin was injected 6 h prior or
subsequent to SRBCs, or when the pigment was administered at the same time as the
SRBCs.
The results generated from this study indicate that pyocyanin has a definite
suppressive effect upon the formation of PFUs in response to a mitogenic stimulus. The
decrease in PFUs was not found to be attributed to cell death from toxicity of the pigment,
thus suggesting that pyocyanin interferes with the humoral immune response mechanisms
of infected hosts. Preliminary data suggests that pyocyanin could also interfere with the
activation of cells and/or subsequent release of cytokines from stimulated immune cells.
However, before any final conclusions can be made, further experimentation needs to be
conducted to specifically delineate the exact mechanism of pyocyanin’s action on the
immune system.
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THE SUPPRESSIVE EFFECT OF PYOCYANIN
ON THE HUMORAL IMMUNE RESPONSE OF
MICE

CHAPTER I
IN T R O D U C T IO N

The Immune Response
Controlling the development or progression of disease within the body involves the
activation of the immune system. This elaborate network consists of both primary and
secondary defense mechanisms (55). Initial protection or innate immunity, is afforded by
cough reflex, stomach acid, mucociliary clearance, and the epithelial barrier, while the
second line of defense involves specific branches of the immune system called humoral and
cellular immunity (55).
For survival, the host depends on an elaborate network of communication between
cells of the immune system for protection from invasion by microorganisms. This internal
network helps to enhance or suppress regulation of humoral and cellular immunity by
interaction with cytokines, or protein mediators which are released from and communicate
with cells of the immune system (47, 55). The humoral and cellular immune branches,
which include T and B-lymphocytes, phagocytic cells, antibody, and complement, work in
conjunction to destroy pathogens and keep the host free from infection (29, 83).
Phagocytic cells are important for defending the body against extracellular pathogens
in both the first and second lines of defense (29, 51, 69, 83). Phagocytosis includes the
ingestion of foreign particles bound by specific receptors and destroyed by oxidative and/or
non-oxidative mechanisms (29, 69). There are several categories of phagocytic cells
including mononuclear phagocytes and polymorphonuclear leukocytes (PMN's) (29, 51,
69).
Mononuclear phagocytes are a group of cells consisting of circulating monocytes and
adherent macrophages (29, 69). These ceils are involved in the first line of defense, but
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they also play an important role in the induction of the cellular and humoral immune
responses (51, 83). Neither of these phagocytic cells exhibit antigenic specificity but they
have the ability to bind and digest foreign particles and antigen. For this reason they are
called antigen presenting cells (APCs) and have the ability to bind to, process and present
antigen resulting in the activation of B and T-lymphocytes (11, 19, 29, 83). Tlymphocytes possess specific receptors which bind to antigen, and in turn, secrete soluble
proteins, or cytokines, which act on B-lymphocyte activation and the subsequent
production of antibodies (83). It is through this cascade that the humoral immune system
can respond to antigen.
Macrophages have two main functions: 1.) to phagocytose and break down materials
for excretion and reutilization, and 2.) antigen processing and presentation (51).
Macrophages possess the ability to phagocytose and destroy not only bacteria, but viruses,
fungi and protozoa as well (51). The occurrence of non-specific phagocytosis by activated
macrophages is variably determined by the presence of antibodies to the bacterium or
invading pathogen (51). Ingestion of a microorganism is dependent on surface properties
and the presence of specific serum ligands, or non-antibody proteins, which interact with
receptors on the surface of the phagocytic cell, as well as the presence of antibodies and
complement (29,51). Ingestion of a particular microorganism is mainly a localized
response, meaning that not all particles which are attached to the phagocytic cell surface
will be ingested (29).
Antigen is processed through partial digestion by lysosomal enzymes within the
macrophage, and presentation includes the displaying of antigen on the cell surface in the
context of a product encoded by the major histocompatibility complex (MHC). This
processed antigen is recognized by the T-cell receptor complex expressed on the surface of
CD4+ and CD8+ T- lymphocytes. The T-lymphocyte receptor and antigen bind, thus
forming a complex on the surface of the macrophage which then triggers the release of
2

cytokines by macrophages (83). As a result of cytokines being released, T-lymphocytes
become activated and thus synthesize more mRNA specific for the expression of different
cytokines which can selectively act upon the growth and differentiation of many immune
cells. B-lymphocytes in close proximity to activated T-lymphocytes are acted upon by
specific cytokines secreted by T-lymphocytes. The activation of B-lymphocytes leads to
their differentiation into antibody-secreting plasma cells. Antibody production is dependent
on this interaction between B and T lymphocytes (3).
The two main functions of B lymphocytes in the immune system are, 1) to serve as
effector cells, thus integrating the humoral immune system, and 2) to process and present
antigen (6). The ability of B lymphocytes to selectively capture antigen and then present it
to T lymphocytes for further processing, is the basis of the first line of defense in the body,
known as the humoral immune system (6, 8).
Cytokines include biologically potent, soluble protein molecules secreted by
lymphocytes and monocytes following stimulation by antigens, lectins, and bacterial
products (2, 12). Lectins are carbohydrate-binding proteins which induce certain cell types
to proliferate upon stimulation. Substances which stimulate lymphocytes to proliferate are
called mitogens, and lectins are a type of mitogen. Concanavalin A (Con A) and
phytohemagglutinin (PHA) are also examples of mitogens which non-specifically stimulate
mitogens. Cytokines in general share certain attributes including being antigen-nonspecific
proteins which are synthesized very rapidly, in small quantities in response to a stimulus
(2, 12, 55, 62, 70, 72). Other shared attributes of these protein molecules include having a
low molecular weight; often being glycosylated; being very potent, acting at picomolar
concentrations, in a short-range paracrine or autocrine function (rather than endocrine); and
lastly, cytokines are also produced locally and are transient (2, 12, 62). In addition,
cytokines are generally involved in immune regulation as well as the extent and duration of
an inflammatory response (62). Cytokines have multiple functions which can overlap and
3

in some instances, may be contradictory, in addition, several different cytokines may act on
the same cell to induce similar functions (2, 8, 62). In addition, some of the interactions on
cellular functions may be additive, synergistic or even antagonistic (62).
There are six categories of cytokines including: interferons (IFN -a, 3, y), cytotoxic
factors (TNF, LT), interleukins (IL-1 through IL-18), hematopoietic colony stimulating
factors (GM-CSF), inflammatory, and transforming growth factors (TGF-p) (2).
Cytokines have a variety of functions, some of which may be unrelated, including:
inflammation, bone resorption, immunomodulation, hematopoiesis, wound healing, and
the ability to induce cachexia and septic shock (2, 62).
Interleukins are a class of cytokines which act on or signal between leukocytes of the
immune system. Interleukins are produced by T-cells, monocytes, and macrophages, and
have such functions as promoting the secretion of antibodies by B cells, enhancing antigen
presentation and phagocytosis by macrophages, as well as functioning as a growth factor
and promoting proliferation and differentiation of both B and T lymphocytes (1, 2, 12, 62,
72). The interleukin nomenclature consists of the letters “IL” followed by a number,
currently, the interleukins include IL-1 through IL-18.
Interferons are a class of cytokines which are capable of modifying or enhancing the
immune response by making T-lymphocytes and macrophages more effective. More
generally, interferons are classified together because of their antiviral and anti-proliferative
properties (62). The interferons include interferon alpha (IFN -a), interferon beta (IFN-f3),
and interferon gamma (IFN-y) (2, 62). IF N -a and IFN-f) both induce resistance to viral
infection (2, 62). In addition, they both exhibit antiproliferative effects on tumor cells and
enhance antigen presentation (2,62). Better characterized, IFN-y, synthesized by T-helper
lymphocytes, enhances the activities of killer T-lymphocytes, natural killer cells, and
4

macrophages (1, 2). IFN-y’s immunomodulative effects include increasing B-lymphocyte
activation, proliferation, and antibody secretion (1, 2). IFN-y induces bacterial killing
through increasing the fusion of the phagosome to lysosome thus triggering an oxygenindependent killing mechanism as well as the generation of toxic oxygen radicals (17).
IFN-y is a widely studied cytokine for it’s antiviral properties, phagocytic cell activation
potential, and the affect on tumor necrosis factor production (2, 72).
Tumor necrosis factor alpha (TNF-a), also referred to as cachectin, is synthesized by
monocytes, macrophages, and lymphocytes and acts on many cells of the immune system,
specifically aiding in the regulation of macrophage activation (17, 72). TN F-a induces
cachexia, which is the severe weight loss associated with malnutrition and cancer patients,
by stimulating the production of the lipoprotein lipase and lipolysis in adipose cells (1,2,
55, 72-73). T N F -a is most widely known for its ability to induce the lysis of certain
tumor cells in vitro and necrosis of certain types of tumors in vivo (1 ,2 , 73).
Immunoglobulins, or antibodies are major glycoproteins of the humoral immune
system (19, 33, 56). Immunoglobulins secreted by B-lymphocytes help rid the host of
foreign invaders through the neutralization of toxins, opsonization, and activation of
complement Antibodies have two main functions which correspond with the two main
regions of the molecule. The Fab region of the antibody, consisting of a variable and
constant region each with a heavy and light chain held together by disulfide bonds (55).
This region is also referred to as the antigen binding fragment, and appropriately it binds to
a certain antigen that it recognizes distinctively (55). The Fc region, which is entirely
composed of a constant region, does not have the ability to bind to antibody, but rather
binds to complement and mediates immune reactions by binding to host cells including
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neutrophils and macrophages (55).
There are five major classes of antibodies: IgG, which accounts for 80% of the total
immunoglobulin concentration in the serum followed by, IgA (10-15%), IgM (10%), IgD
(less than 1%), and IgE (0.01%) (13, 33, 56). IgG is one of the most biologically active
antibody, able to neutralize bacterial toxins (56). PM N’s and macrophages possess
receptors for IgG which promotes phagocytosis of bacteria (25, 56). IgG is also the only
immunoglobulin that can cross the placenta, providing antibody protection to the fetus (25,
56). IgM is the first immunoglobulin synthesized in response to antigen, it is also the
largest. IgM can be found in serum in its pentameric form and it also exists as a hexamer.
B-lymphocytes express IgM on their surface. IgM is one of the most important
immunoglobulins in the immune system. IgA is present in the serum in small amounts, but
is also a secretory immunoglobulin. Secretory IgA is the main immunoglobulin present in
external body secretions including tears, saliva, urine, and colostrum; it possesses a
secretory component which makes it relatively resistant to digestion by proteolytic enzymes
which are present on mucosal surfaces (51). Although the anti-bacterial activity of IgA has
not been well characterized, it is thought that IgA aids in the inhibition of attachment and
subsequent growth of bacterial cells to mucosal surfaces (25, 29-30). Not much is known
about the capacity of IgE in host defense, however it’s role in type I hypersensitivity
reactions (i.e., allergies) has been well characterized (11, 29). It is likely that the release of
histamines and other vasoactive substances from mast cells and basophils in a
hypersensitivity reaction may function in increasing the concentration of other
immunoglobulins to the site of antigenic entry (29, 51).
Upon primary exposure to antigen, B-lymphocytes undergo clonal expansion and
differentiate into antibody-secreting plasma cells specific for that antigen (51, 55). The
type of immunoglobulin secreted by the B-lymphocyte is dependent on the stimulus
received by the cell. Cytokines also have a role in antibody production as they aid in the
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isotype switch (switch from production of IgM to IgG, IgA, etc.) of B-Iymphocytes (55).
All the components of the immune system have a role in the intricate network which
functions in keeping our bodies free from infection. Individuals who have intact immune
systems, in the absence of underlying disease, can successfully fight off infection from
invading microorganisms. There are those however, who cannot achieve this balance due
to severe trauma or illness, and therefore generally succumb to infection by opportunistic
pathogens.

Pseudomonas aeruginosa
Pseudomonas aeruginosa is a gram negative bacillus which may be found as a free
living saprophyte in soil, fresh or marine water, and other natural ecosystems or may exist
as an infectious agent in association with plants, animals, and man (15, 20, 22, 38, 40).
Pseudomonas possesses ubiquitous growth characteristics which better suites it for
survival in harsh environments as compared to the enteric microorganisms (15, 42). Some
of these characteristics include the ability to grow at higher temperatures (43 °C), and the
ability to survive indefinitely in aqueous environments, including distilled water, at room
temperature (20, 42, 57-60, 76). The bacteria's simple nutritional requirements include
multiple low molecular weight organic compounds, preferably organic acids, and has even
been known to employ certain antimicrobial agents such as phenol and penicillin (22). P.
aeruginosa possesses a large reserve of enzymes which allows it to use multiple
substances as nutrients and adapt to changes in it’s environment (15). Pseudomonas can
also utilize a few monosaccharides, however it cannot use any disaccharides or
polysaccharides (22).
Traditionally thought of as obligate aerobes, some species of pseudomonads can use
nitrate as the terminal electron acceptor in the absence of oxygen (20, 76). Pseudomonas
can also make use of the amino acid arginine in anaerobic environments by converting it to
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ornithine via the arginine dehydrolase enzyme pathway (76). Although pseudomonads are
non-fermentative, the ability to utilize nitrates, and in some instances, arginine, contributes
to the ubiquitous growth in soils and even hospital environments (76).
This aerobic, non-spore forming bacteria varies in size from 1-3 pm in length and
0.5-1.0 pm in width (20, 21). The motility of Pseudomonas is dependent on the number
and position of flagella which differ between strains (22). However, motility is an
important factor in Pseudomonas aeruginosa infections which become systemic,
particularly thermal bum injuries and chronic cystic fibrosis (CF) infections (15). As with
most gram negative bacteria, Pseudomonas possesses an outer membrane composed of
lipoproteins, phospholipids, and lipopolysaccharide (LPS). The outer membrane serves as
a protective agent in bacteria acting as a permeation barrier to chemical agents (22).
Between the outer membrane and the cell membrane exists the periplasmic space which
contains many hydrolytic enzymes. Particular strains of Pseudomonas aeruginosa may
also have a layer of acetylated exopolysaccharide or alginate layer which is useful in
adherence. This mucoid exopolysaccharide layer, composed of mannuronic and guluronic
acids, provides a selective growth advantage to Pseudomonas aeruginosa by interfering
with phagocytosis, specifically, with chemotaxis and ingestion by neutrophils and
macrophages (48, 49, 63, 69).
Pseudomonas aeruginosa is often referred to as an opportunistic human pathogen (5,
22, 30-32,48, 76). It is the leading cause of morbidity and mortality in compromised
hosts, including individuals with decreased phagocytic or complement function, as well as
those with agammaglobulinemia, hypogammaglobulinemia, or a deficiency in IgM (5, 22,
30-32,48, 76). It may also cause disease in other vertebrates, invertebrates, and even
plants. Fresh fruits and vegetables have been traced as colonization vectors for infected
patients in hospitals (22, 38). Although seven to twenty-five percent of healthy individuals
carry Pseudomonas in their intestinal tract, they do not exhibit clinical symptoms or
8

significant stimulation of their immune systems (20, 38). Those individuals frequently
colonized with Pseudomonas are immunocompromised and include thermal bum, cancer
and CF patients (5, 15, 16, 22, 30-32, 38-40, 42, 48, 50, 57-59, 63-69, 75-76).
Pseudomonas aeruginosa is a predominant component of bum wound flora,
colonizing about sixty percent of patients by the 5th day post bum (15, 22). After a bum
injury, proteins which are destined to become part of the protective antibodies of the
immune system in these individuals are diverted for more immediate functions, thereby
leaving room for colonization by bacteria (22, 44). In addition, various aspects of
neutrophil function, including chemotaxis, may be damaged in these patients, leaving them
susceptible to infection (66). Colonization and infection by Pseudomonas aeruginosa in
these patients is a major threat and cause of morbidity and mortality (7, 15, 22, 30-32, 5759, 63-69).
The frequency of Pseudomonas bacteremia is extremely high in cancer patients and
accounts for over twenty-five percent of deaths involving children with leukemia (22,69).
These infections are predominantly nosocomial (42, 44, 69). Individuals undergoing
chemotherapy, or with acute leukemia, bone marrow cancer, or any other secondary
malignancy which leads to neutropenia often have a high incidence of P. aeruginosa
infection (15, 22,69). Mortality in cancer patients generally ensues as a result of extreme
leukopenia or a severe decrease in the levels of opsonizing antibodies for Pseudomonas
aeruginosa (30-32). There has been some success in recovery from these infections in
some cancer patients, with gamma globulin administration (30-32).
Pseudomonas aeruginosa bacteremia in CF patients is mainly confined to the lung and
bronchial area until late in disease progression (7, 57, 58, 65, 69, 76). The bacteria is
isolated from the sputum of infected patients approximately ninety percent of the time (57).
It is speculated that a possible defect in the mucociliary transport system of CF patients is
attributed to the chronicity of P. aeruginosa infections (60). Speert (1993), using CF
9

leukocytes and serum, found that phagocytosis was compromised in vitro due to
alterations in receptor and opsonic function (69). Isolates recovered from infected CF
patients appear to be highly motile (59) and more mucoidal than strains of Pseudomonas
recovered from other types of infections (7, 15, 22, 76). There has not been a single
documented case of full recovery or cure of a CF patient infected with P. aeruginosa (57).
It is difficult to characterize the pathogenesis of Pseudomonas aeruginosa due to the
range of disease it causes from the acute infections seen in bum patients and those with
endopthalmitis (an eye infection caused by Pseudomonas ), to the less frequently seen bone
and joint infections, endocarditis, meningitis, and malignant external otitis, to the
predominant chronic lung infections of CF patients (15, 76). Although this microorganism
infects non-compromised individuals, the highest morbidity and mortality is found in the
immunocompromised population, particularly those with CF and cancer (16, 22, 44, 48,
66, 69, 76). More than eighty percent of Pseudomonas isolates from CF patients are
mucoidal, in contrast to the smooth and rough forms isolated from other infections (76).
The mucoidal or alginate form, composed of B-1,4 linked mannuronic acid and L-guluronic
acid, is one of the most important virulence factors of Pseudomonas (15, 69, 76). More
than eighty percent of P. aeruginosa isolates from chronically infected CF patients possess
this mucoidal alginate layer as compared with only 2.5 % of Pseudomonas recovered from
other types of infections (76). Alginate production is an unstable characteristic in that it is
inducible and the moist environment of the lung appears to encourage it’s production (76).
Alginate production contributes to the pathogenesis of P. aeruginosa lung infection similar
to that of other polysaccharides in that it helps in the adherence of the bacterium to the moist
environment of the lung, and also has anti-phagocytic properties (15, 22). Buret and
Cripps (1993) have also found that the alginate layer may interfere with normal opsoninreceptor associations by prevention of antibody-complement coating (16, 38). It has also
been suggested that in the presence of calcium, alginate forms a protective gel-like matrix
10

around the bacterium which shelters it from host defenses and possibly the actions of
charged antibiotics (76).
Pseudomonas aeruginosa produces many extracellular products, some very toxic to
hosts, and others of little or unknown toxicity. These factors include exotoxin A,
phospholipase C, numerous proteases, phenazine pigments, and alginate (15, 22, 36, 39,
57-60, 76). Exotoxin A has been identified as the single most toxic substance, based on
weight, produced by Pseudomonas aeruginosa during acute infections (57-60, 76). The
enzyme activity of exotoxin A is identical to that of diphtheria toxin in that it interferes with
protein synthesis (36, 76). More specifically, exotoxin A catalyzes the transfer of the
ADP-ribosyl portion of NAD onto eukaryotic elongation factor 2, a substance which is
critical to protein synthesis at the ribosomal level (36, 76, 81-82). Moreover, the
production of both exotoxin A and diphtheria toxin is regulated by iron concentration, thus
when iron levels are insufficient enough to allow for optimal growth of Pseudomonas, then
exotoxin A is produced (76, 81-82). The effects of exotoxin A in vitro includes being
cytotoxic to mammalian cells in culture, as well as impairing the ability of human
macrophages to exhibit phagocytic activity (81-82). In animal studies, Vasil (1986) found
that in the chronically infected rat lung, the production of exotoxin A contributed to
virulence of infection, but was not essential for increased pathogenicity (76).
Pseudomonas exoenzyme S functions much in the same manner as exotoxin A in that
it affects ADP ribosyl transferase activity (61, 66, 82). Exoenzyme S has not been
characterized as well as exotoxin A, but in studies involving the chronically infected rat
lung, strains of P. aeruginosa that did not produce exoenzyme S were not as virulent as
those that did, indicating that exoenzyme S may have a role in the pathogenicity of
chronically infected patients (76, 82). Elastase and alkaline proteases, also called
aggressins, have been found to contribute to the destruction of lung connective tissue as
well as altering the cell receptors for opsonins including antibodies and complement,
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contributing to the persistence of infection (61,66, 76). Elastase and alkaline protease
have also been found to degrade IL-2, and to a lesser extent, IFN-y and TN F-a (15).
These toxins have also been found to inactivate the humoral immune response through the
proteolysis of IgG and IgA, inhibit natural killer cell activity, decrease the expression of the
CD4 molecule on T-helper lymphocytes, and inhibit lymphocyte proliferation (15, 36, 60,
66, 75-76).
Phospholipase C is a heat-sensitive hemolysin produced by Pseudomonas (76).
Much like exoenzyme S, it has not been studied as carefully as exotoxin A, however, it has
been found to hydrolyze certain phospholipids, which are important components of
eukaryotic cell membranes (76). Hydrolysis of phosphatidylcholine, a major component of
lung surfactant, by phospholipase C could contribute to the virulence of P. aeruginosa in
the lung (76, 82).
The production of pyocyanin, a blue phenazine pigment, is the distinguishing factor
between P. aeruginosa and other pseudomonads. Pyocyanin (5-methyl-l-hydroxy
phenazium betaine) is only one of several phenazine pigments produced by this bacteria;
others include 1-hydroxyphenazine, oxychlororaphine, phenazine-1-carboxylic acid,
chlororoapine, and aeruginosin A and B (4, 63). Because pyocyanin is produced by
approximately fifty percent of all clinical isolates, it is the only one thought to contribute to
the virulence of P. aeruginosa and may be linked to this microorganisms ability to acquire
certain essential nutrients, including iron (17, 19-20, 37-38, 41, 60, 65, 74).
Pseudomonas aeruginosa is highly resistant to most conventional forms of antibiotic
therapy as well as most chemical agents (24, 36, 44). Being one of the microorganisms
that possesses inducible B-lactamases, Pseudomonas is resistant to virtually all the B-lactam
antibiotics (i.e., penicillins) (44). The pseudomonads are more resistant to chemical agents
as compared to other gram negative organisms possibly due to the outer membrane, which
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acts as a permeation barrier to chemical substances. Although all gram negative organisms
possess this unique characteristic, the LPS layer, which is one of several components
which comprise the outer membrane, of Pseudomonas aeruginosa differs from that of
Escherichia coli in that the composition of the lipid A portion contains a greater array of
hydroxy fatty acids (22). Another difference between the two LPS layers is the presence of
exotic amino acids and sugar acids in the O-specific polysaccharide region of P. aeruginosa
in contrast to the simple sugars present in that of E. coli. This may contribute to the
greater diffusion barrier for pseudomonads (59). Pseudomonas is not resistant to all
chemical agents, however, it is sensitive to ethylenediaminetetraacetic acid (EDTA) and
polymyxin (20).

P h e n a z in e p ig m e n t p r o d u c tio n

Phenazines are low molecular weight compounds containing 3 heterocyclic rings with
nitrogen substitutions at the 5th and 10th carbons. These naturally occurring pigments are
formed exclusively by bacteria as secondary metabolites, and can be classified into 3
groups according to the number of carbon susbstituents (0, 1, and 2) (68, 74, 77, 79).
The relatively inactive parent compound which serves as the basis for many biologically
active derivatives, has no end groupings and is uncharged (Fig. 1). It carries a molecular
weight of 180.2 and can be reduced in both aqueous and non-aqueous media (68, 74, 77,
79).
Well over 50 phenazine pigments are known representing every color of the visible
spectrum. The absorption spectra of phenazines include characteristic peaks, including an
intense peak in the 250-290 nm range and a smaller peak at 350-400 nm. Phenazine
pigments, excreted by bacteria into medium, are mostly soluble in aqueous and organic
solvents (26-27, 68).
Pyocyanin is a phenazine pigment produced mainly by Pseudomonas aeruginosa and
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by Streptomyces cyanoflavus (4, 68). This heat resistant, low molecular weight (210.3)
pigment diffuses readily into medium and stains blue in alkaline conditions and deep red in
acidic environments. This redox dye is zwitterionic in nature, thus confirming it's
solubility in aqueous and organic solvents including: chloroform, hot water, ethanol,
acetone, glacial acetic acid, and phenol (68, 74). Pyocyanin is slowly degraded to 1hydroxyphenazine in the presence of ultraviolet light, and becoming yellow in color when
neutralized (68, 74, 77, 79). One-hydroxyphenazine, or hemipyocyanine, is often found
in aged P. aeruginosa culture supernatants appearing purple-red in alkaline conditions.
This low molecular weight (196.2) compound carries no charge.

P y o c y a n in

First seen in the 1850's on the dressing of wounds, the characteristic blue-green
colored pus was viewed as a sign that an infection was impeding healing (26).
Successfully isolated in 1859 by Fordos, the name pyocyanin was given to the pigment,
thus leading to the original naming of P. aeruginosa as Bacillus pyocyaneus (68, 74).
Ironically, pyocyanin has been found to possess certain antimicrobial properties, thus
allowing for the opportunistic growth of Pseudomonas aeruginosa (4, 9-10, 18, 65, 68,
74). The antibiotic activity is directed mainly against gram positive organisms, including
common respiratory pathogens such as Hemophilus influenzae. Most gram negative
organisms and all pseudomonads are resistant to pyocyanin. The antibiotic effect of this
bacterium is suspected to be dependent on active bacterial respiration rather than the
presence or absence of oxygen as originally thought (9-10, 68). This suggests that
pyocyanin may be active at several specific sites of the bacterial respiratory chain.
Armstrong et al. (1979) found that 1-hydroxyphenazine inhibited the uptake of
oxygen by mouse liver mitochondria at the cytochrome b site (5, 64-68, 71). The
suggested mechanism for this is that the outer mitochondrial membrane is permeable to all
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molecules with a molecular weight of 10,000 daltons or less. However, most compounds
cannot permeate the inner membrane where the respiratory enzymes are housed.
Pyocyanin has been found to inhibit reactions necessary for specific host defense including
the proliferation of T lymphocytes, production of IL-2 and expression of IL-2 receptors,
the activity of cytotoxic cells, and secretion of antibodies (44, 48-49, 59-60, 63-67, 69).
Pyocyanin has been identified as the heat resistant compound found to inhibit lymphocyte
proliferation when cell-free Pseudomonas aeruginosa supernatant was added to
lymphocytes in culture (68). Pyocyanin has also been found to inhibit lymphocyte
proliferation in response to antigens and mitogens and the expression of IL-2 receptors as
well as the secretion of IL-2 (48, 59, 75, 80). The inhibition of mitogen-induced
lymphocyte blastogenesis is speculated to occur at a step past the initial increase in free
cytosolic calcium (64, 67). There may also be specific cell receptors for pyocyanin on
immune cells, however any binding that may occur is probably non-covalent given the fact
that the effect of pyocyanin on lymphocytes is reversible after washing (63-64). Blymphocytes have also been found to be affected by the actions of pyocyanin. The
secretion of antibodies by B-lymphocytes have been reduced at concentrations between 0.1
and 0.2 ^g/ml (71). It has also been found that mitogenic stimulation of B-lymphocytes
can be achieved with concentrations of pyocyanin of 0.2 /^g/rnl or higher (71).
In vivo, pyocyanin has been found in the sputa of infected CF patients at
concentrations as high as 27 ^g/ml (34). Pyocyanin has been shown to enhance the
oxidative metabolism of neutrophils thus, impeding ciliary beat movement by generation of
toxic oxygen radicals through the activation of mucosal neutrophils (34, 60, 80). It has
also been previously reported that pyocyanin inhibits the uptake of molecular oxygen by
mouse monocytes, HeLa cells, isolated mouse liver mitochondria, cultured BHK cells, and
intact guinea pig peritoneal macrophages (5, 45, 49-50, 80). The suspected mode of action
is the inhibition of electron transport by action upon the ubiquinone, cytochrome b site
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(45).

R e se a r ch O b je c tiv e s

Pseudomonas aeruginosa is an opportunistic pathogen implicated in the colonization
of bum victims as well as the lungs of individuals with CF. Pseudomonas produces
several exoproducts many of which aid in the colonization of hosts as well as contributing
to the virulence of infection and resistance to antibiotic therapy. The phenazine pigment,
pyocyanin, a by-product of Pseudomonas aeruginosa , has been widely studied as an
inhibitor of not only cellular functioning, but also of certain aspects of the immune
response, thus contributing to virulence of infection. Therefore, it was important to focus
this research on the effect, if any, of pyocyanin on the humoral immune response of mice.
The primary objective of this research is to identify the effect, if any, of intravenously
administered pyocyanin on splenic cells of mice involved in the humoral immune response.
Next, experiments will be designed to ascertain the kinetics of this response. For example,
is there a difference if pyocyanin is given prior to, at the same time, or after SRBCs. The
final objective is to examine the effect, if any, of pyocyanin on specific cytokines involved
in the generation and maintenance of a humoral immune response.
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C H A P T E R II
M A T E R IA L S A N D M E T H O D S

A n im a ls

B6D2F] (C57BL/6J x DBA/2J) mice of both sexes ranging in age from eight to ten
weeks were used in all experiments. Breeder mice were obtained from Jackson
Laboratories (Bar Harbor, Maine). BDFi mice were bred and raised in the animal housing
complex in the Department of Biology at the University of Dayton.

C u ltu r e M ed ia

Minimal essential media (MEM-Eagle) and RPMI-1640 (10.39 g RPMI-1640 media,
5.96 g HEPES, 10 ml L-glutamine stock, 2 g NaHCO3, pH 7.2-7.4) were used in all
experiments involving injection of animals and culturing of cells. Antibiotics [penicillin
(10,000 U/ml), streptomycin (10,000 ^g/ml), and gentamicin sulfate (10 mg/ml)] were
added to RPMI-1640 used in cell culturing. All media was filter-sterilized using 0.2 /zm
pore size filters and stored at 4 °C.

P r e p a r a tio n a n d P u r ific a tio n o f P y o c y a n in

The photochemical reaction using the phenazine methosulfate (PMS) method of
Knight el al. (1979) was adapted in order to prepare pyocyanin (37). A 0.5 mg/ml solution
of PMS [48 mg PMS in 96 ml of 0.01 M tris(hydroxymethyl)ami nomethane buffer, pH
7.0] (Sigma, St. Louis, MO) was illuminated for approximately 18 h at room temperature
under an intense fluorescent lamp until the yellow solution turned deep blue. The blue
solution was then transferred to a glass lyophilizing flask, shell-frozen with dry ice, and
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lyophilized. The lyophilizate was dissolved in 2 ml of methanol, and absorbed onto a silica
gel column (Merck, grade 9385, 230-400 mesh, 60

A ).

Pyocyanin was eluted with a 20%

methanol-chloroform mixture using flash chromatography. The blue fractions were
collected in 10 ml quantities, pooled, and evaporated to dryness. Approximately 10 mg of
the blue crystals were dissolved in chloroform and the purity was checked by proton
nuclear magnetic resonance (NMR). The scan revealed a high water content so the crystals
were evaporated for 4 days under vacuum. The crystals (10 mg) were dissolved in 1 ml
warmed RPMI-1640 for use in experimentation. The remaining pyocyanin was stored in
1.5 ml eppendorf tubes at 4 °C until further use.

P r e p a r a tio n o f S h e e p R ed B lo o d C e lls (S R B C )

Approximately 2 ml SRBC (Colorado Serum, Denver, CO) in Alsevers solution were
washed twice in 0.85% sterile saline at 1,500 rpm and spun in a Beckman centrifuge before
each experiment. After the second washing, the pellet was resuspended in RPMI-1640 to a
final concentration of 10% for injection into animals, and 12% for use in hemolytic plaque
assay.

In je c tio n o f A n im a ls

Mice were given intravenous (i.v.) injections of either RPMI-1640, SRBC, or
pyocyanin via the tail vein. Initially, mice were divided into five groups, consisting of a
positive and negative control, and three experimental groups. Mice receiving media alone
served as the negative control, while the positive control consisted of mice injected with a
10% suspension of SRBC. Experimental groups received the SRBC suspension plus
either (A) 0.1 ml (1.0 /rg) pyocyanin, (B) 0.1 ml (10.0 //g) pyocyanin or (C) 0.1 ml
(100.0 //g) pyocyanin. The optimal dose was determined to be 1.0 ^ g concentration of
pyocyanin and was used for all subsequent experimentation. Further experimentation
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included mice being divided into five groups, consisting of a positive and negative control,
and three experimental groups. Mice receiving media alone served as the negative control,
while the positive control consisted of mice injected with a 10% suspension of SRBC.
Experimental groups received either: (A) 0.1 ml pyocyanin and SRBC at the same time, (B)
0.1 ml pyocyanin 12 h prior to SRBC, (C) 0.1 ml pyocyanin 6h prior to SRBC, (D) 0.1 ml
pyocyanin 6 h post injection with SRBC, and (E) 0.1 ml pyocyanin 12 h post injection
with SRBC.

C ell V ia b ility

The spleens of control and experimental animals were removed at different intervals,
weighed, and cell viability assessed by trypan blue exclusion. In this experiment, one
mouse served as the control and received 0.1 ml MEM i.v., while the 5 experimental mice
were injected with 0.1 ml of 10 /^g/ml (1.0 /<g) pyocyanin i.v. at the same time. At 2, 4,
6, 12, and 24 h intervals, the spleen of the animal was removed and weighed. A single cell
suspension was made by gently teasing the spleen to release the cells using 1 x 2 toothed
forceps, into approximately 1 ml of media. The cells were washed once in MEM and
centrifuged for 10 min at 1,500 rpm, then resuspended in 2 ml MEM. In order to remove
the red cells, the cell suspension was pelleted by centrifugation at 1,500 rpm for 10 min
and 1 ml red cell lysing buffer (Sigma, St. Louis, MO) was added. The tube was then
placed on a Nutator rotator for 1 min. The cells were pelleted again by centrifugation and
resuspended in 2 ml MEM. A 1:10 dilution of cells (1 ml) was made using MEM, and 0.5
ml of the diluted cells was transferred to a 12 x 75 mm disposable test tube containing 0.5
ml of 0.2% trypan blue, mixed thoroughly, and the cells were immediately counted using a
hemocytometer. The cells which excluded the blue dye were considered viable. The
percentage of live cells was derived from the ratio of live to dead cells, then compared
against the values from the control animal which were counted at each time interval.
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L y m p h o c y te P r o life r a tio n A ssay

Three normal animals were sacrificed, their spleens removed, and a single cell
suspension made. The cells were washed in RPMI-1640 by centrifugation (10 min at
1,500 rpm), resuspended in 2 ml RPMI-1640, then counted. The cells were resuspended
at a concentration of 4 x 106 cells/ml in R.PMI-1640 supplemented with antibiotics and 4%
fetal calf serum (FCS) and 0.1 mJ dispensed into individual wells of a sterile 96 well
microtiter plate (Coming). Quadruplicate wells received either 0.1 ml RPMI-1640 alone,
LPS (1.0 /ig/well), concanavalin A (Con A) (0.1 /zg/well), or pyocyanin (0.05 ^g/vvell,
0.1 //g/well, 0.5 /^g/well, 1.0 //g/well, and 10.0 /zg/well). The plates were incubated at 37
°C with 5% CO? for 54 h then pulsed for 18 h with 0.1 pCi 3H-thymidine. After 72 h the
cells were harvested onto glass fiber filter paper using a cell harvester. The filter paper
disks were allowed to dry overnight and were placed in 4 ml of scintillation fluid and
counted on a scintillation counter (Beckman LS-3801).

H e m o ly tic P la q u e A ssa y

The humoral immune response in spleen cells was determined using a standard
hemolytic plaque assay (Jeme etal., 1954) (33). In each experiment, mice received either
0.1 ml of a 10% SRBC suspension i.v. on day 0, or 0.1 ml of a 10% SRBC suspension
plus different concentrations of pyocyanin. On day 4, the mice were sacrificed and their
spleens removed. A single-cell suspension was made from the spleens of the mice and the
cells were washed in RPMI-1640 and centrifuged for 10 min at 1,500 rpm. The spleen
cells were then resuspended in 2 ml RPMI-1640. Five hundred microliters of 0.6%
agarose in RPMI-1640 was dispensed into 12 x 75 mm disposable test tubes and placed in
a heated water bath (50 °C). Fifty microliters of a 12% SRBC suspension in RPMI-1640
was dispensed into each of the tubes. Duplicate dilutions (1:10, 1:40, 1:100, and 1:400) of
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the spleen cells from control and experimental mice were added to the tubes. The tubes
were individually finger vortexed and the contents poured onto pre-coated microscope
slides. When the agarose mixture solidified, the slides were inverted onto trays containing
a 1:30 dilution of guinea pig complement in RPMI-1640 (Colorado Serum, Denver, CO).
The trays were then placed in assay boxes and incubated for 3 h at 37 °C with 5% CCb.
After the 3h incubation period, the individual slides were immediately examined for
plaques. Plaques were defined as being a clear-zone in the agar, and were counted using a
magnifying glass. In order to determine the number of plaque forming units (PFUs) per
106 cells, the number of plaques on the slides was multiplied by the dilution used, and that
value divided by the total number of spleen cells (determined by the cell count).

Iso la tio n o f A d h e r e n t M o n o n u c le a r C ell P o p u la tio n

Spleen cells from control and experimental mice were resuspended in RPMI-1640
and 5% fetal calf serum (FCS) to a final concentration of 1 x 106 cells/ml and dispensed
into 150 x 15 mm petri dishes (Labcraft). The petri plates were incubated for 1.5 h at 37 °C
and 5% CO2. After incubation, the media containing the non-adherent cells was decanted
into 50 ml centrifuge tubes (Labcraft) and the plates were rinsed once with warmed (37 °C)
RPMI-1640 to ensure removal of all non-adherent cells. The non-adherent cells were
centrifuged for 10 min at 1,500 rpm. Warmed (37 °C) RPMI-1640 was poured into the
plates and they were gently scraped using a cell scraper to remove the adherent cell
population. The adherent cell population was brought to a final concentration of 1 x 107,
and total RNA was isolated. This cell population consisted mainly of macrophages and
monocytes.
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Iso la tio n o f N o n -a d h er e n t C ell P o p u la tio n u sin g a P erco ll G ra d ie n t

The non-adherent cells recovered from the above procedure were centrifuged and
counted. The non-adherent cells were enriched for T-lymphocytes using a Percoll (Sigma)
gradient equilibrated at 320 mOsm. A 90.86% working solution of percoll and lOx Hanks
balanced salt solution (HBSS) was used to create gradients of 70, 65, 60, 55, 50, and 30%
Percoll diluted in lx HBSS. Two milliliters of each Percoll percentage were gently layered
into a sterile 15 ml centrifuge tube (Labcraft) which was pre-coated with FCS. Non
adherent cells (at a concentration of 5 x 107) were gently layered onto the gradient and
centrifuged at 1,500 rpm for 20 min with the brake off. The cells from fraction 3 (50%
percoll), enriched for T cells, were collected using a sterile pasteur pipette. The cells from
these fractions were washed twice with RPMI-1640 (10 min at 1,500 rpm), resuspended in
2 ml and counted. The cells were brought to a final concentration of 1 x 107 and the total
RNA was isolated.

R N A Is o la tio n

Total RNA was isolated from three groups of spleen cells: unseparated, adherent, and
non-adherent populations from control and experimental groups including those treated
with pyocyanin (1.0 /rg). Prior to RNA isolation, the red cells were lysed. The RNAzol
BTM (Friendswood, Texas) method was used to isolate total RNA. RNA was extracted
from a total of 1 x 107 cells in each instance. The cells were centrifuged in a sterile
microcentrifuge tube at 400 xg for 10 min (Eppendorf 5415 microcentrifuge). The
supernatant was aspirated and the pellet was gently resuspended in 1 ml RNAzol B. One
hundred microliters of chloroform was added to the homogenate and the contents were
vortexed for 15 seconds then centrifuged at 10,000 xg for 15 min at 4 °C. After
centrifugation, two layers formed: an upper aqueous layer containing RNA, and a lower
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phenol-chloroform phase which contained the DNA and protein. Approximately 450 ml of
the aqueous phase was transferred to a sterile microcentrifuge tube and an equal volume of
isopropanol was added. The tube was mixed by inversion and incubated on ice for 2-4 h
or placed in -20 °C overnight. After the incubation period, the tube was centrifuged at
10,000 xg for 30 min at 4 °C. The precipitated RNA formed an off-white pellet at the
bottom of the tube. The supernatant was carefully removed and the pellet washed with 1
ml 75% ethanol in diethylpyrocarbonate (DEPC) treated water (Sigma) and centrifuged at
10,000 xg for 8 min at 4 °C. The supernatant was again carefully removed and the pellet
was allowed to dry. The dried pellet was dissolved in 10 //I of DEPC water. To measure
the concentration of the extracted mRNA, 1 /zl of the mRNA suspension was placed in 69
/ri of DEPC water in a microcuvette, and the absorbance was read at 260 and 280 nm on a
spectrophotometer. The concentration was determined using the following formula:
A260mn x dilution x 40 = /rg RNA/ml. The isolated RNA was stored at -20 °C until further
use.

P r e p a r a tio n o f cD N A

Two micrograms of RNA was suspended in a total of 9 /d of DEPC-treated TEO.
The samples were heated at 70 °C for 10 minutes in a thermocycler (Thermolyne) then
quick chilled on ice for 5 minutes. Ten microliters of the Promega reaction mixture [4 pi
M-MLV RT 5x buffer, 2 /d 10 mM dNTP, 2 pi random hexamers, 2 pi M-MLV RT
(RNAse minus), 1pi RNase inhibitors] was added to each sample, and incubated at room
temperature (approximately 25 °C) for 10 min. The samples were then incubated in the
thermocycler at 37 °C for 60 min. After this time, the reaction temperature was increased to
95 °C for 10 min. The reaction mixture was quick chilled again in the thermocycler at 4 °C
for 30 min.
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P o ly m e r a se C h a in R ea ctio n (P C R )

A PCR master mix was prepared by multiplying the volume of each reagent by the
number of samples plus 1. One microliter of cDNA from each sample was added to new
sample tubes along with 49 /d of the master mix (per sample: 5 //I 10 x PCR buffer without
Mg2+, 3 //I 25 mM MgCl2, 0.5 /d 10 mM dNTP, 1 //I primer, 0.2

Taq DNA

polymerase (5000 u/ml), and 39.3 /d DEPC-treated H2O) all from Promega. The tubes
were centrifuged at 10,000 xg for 10 sec in an Eppendorf 5415 microfuge and overlayed
with 50 ]A of sterile mineral oil (Sigma). The samples were placed in the thermocylcer
heated to 95 °C for 5 min, then 55 °C for 1 min, and 72 °C for 1 min followed by 35 cycles
of 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min.
The PCR products and DNA ladder molecular weight marker were run on a 2%
agarose gel (dissolved in lx TBE) with 1.5 //I of 10 ^g/ml ethidium bromide. Sixteen
microliters of PCR product and 5 ml of loading dye were loaded and run (700 ml lx TBE)
for 1 hour at 120 volts. The gel was examined under ultraviolet light and photographed.

S ta tis tic a l A n a ly s is

The mean, standard deviation, and standard error were calculated for each experiment
yielding PFUs. The standard error is represented as an error bar in each graph. The
statistical significance of the results was calculated using a single factor Anova (P <0.05) to
compare the controls to each treatment with pyocyanin, as well as comparing the treatments
with pyocyanin to each other. The statistical significance of the results is reported in the
figure legend of each graph.
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CHAPTER III
RESULTS

P u r ific a tio n o f p y o c y a n in

Pyocyanin is a phenazine pigment produced by Pseudomonas aeruginosa thought to
contribute to the virulence of infection by this bacterium. Fordos tried to characterize this
pigment in 1859 after the appearance of a blue-green stain on the bandages of infected
individuals (26, 68). Although pyocyanin exhibits antibiotic action against several gram
positive organisms, such as Staphylococcus aureus, it also inhibits the growth of cells in
culture and at concentrations above 2 mg is lethal to mice upon injection (9-10, 66, 68).
To initiate studies addressing the impact of pyocyanin on immune responsiveness, it
was first necessary to obtain a purified preparation of this phenazine compound.
Pyocyanin was initially isolated from actively growing Pseudomonas aeruginosa cultures
using the method of Baron et al. (10). This involved growing large amounts (4 L) of
bacteria for 96 h, centrifuging out the cells, and extracting the dark purple supernatant
several times with chloroform. This procedure yielded only a small amount of pyocyanin,
while the majority of the supernatant was 1-hydroxyphenazine. The concentration of
pyocyanin was very difficult to determine using the method of Baron et al. (10), due to the
small quantity. This technique was abandoned after further literature reviews revealed that
purification of PMS would provide a more efficient way of obtaining pyocyanin.
PMS was converted to pyocyanin via a photochemical reaction in a method adapted
from Knight et al. (37). Flash chromatography eluted with a chloroform-methanol solution
(20%) was used to purify the pigment, then concentrated during lyophilization.
Spectrophotometric analysis as well as a proton NMR confirmed the presence and purity of
pyocyanin. Figure 1 illustrates the structures of the parent phenazine compound,
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pyocyanin, and 1-hydroxyphenazine the breakdown product of pyocyanin. Figure 2 is the
proton NMR of the product obtained from the purification of pyocyanin previously
described in the methods section. Ten milligrams of the compound were dissolved in
chloroform and analyzed for its structure via proton NMR. The proton NMR reveals that
this compound is pyocyanin due to the peaks which appear in appropriate places on the
spectrum. Tetramethyl si lane (TMS) is a standard used in order to get a first peak reading.

T h e e ffe c t o f p y o c y a n in on th e h u m o ra l im m u n e r esp o n se

To determine what effect, if any, this phenazine pigment would have on immune
function, different concentrations of pyocyanin (1.0, 10.0, and 100.0 ^g) were injected
into mice on day 0, simultaneously with a ten percent suspension of SRBC. On day 4 after
the injection, the spleens were removed and the number of PFUs were determined by the
hemolytic plaque assay adapted from the method of Jeme et al. (33) and Mishell et al. (45).
Pyocyanin (1.0 ^g) produced the greatest effect, resulting in a 74% reduction in the
number of PFUs (Fig. 3) and was used for all subsequent experimentation.
To be certain that the observed suppression in Figure 3 was not due to either toxicity
of pyocyanin or endotoxin associated with the purification of pyocyanin, the percent
viability of spleen cells obtained from animals treated in vivo with pyocyanin was
determined by trypan blue exclusion. The percent viability of spleen cells obtained from
experimental animals was never less than 87%, which was not significantly different from
control animals (Table 1).
Previous research has shown that LPS or endotoxin, at appropriate concentrations,
can suppress the immune response. Pyocyanin, obtained from PMS could have been
contaminated with LPS or endotoxin during the purification procedure. To address this
issue, a lymphocyte proliferation assay was performed, based on the fact that LPS is a
known B-cell mitogen. Data in Table 2 illustrates that pyocyanin is not mitogenic at the
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Figure 1.

The structures of the phenazine, pyocyanin, and 1-hydroxyphenazine.
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1-Hydroxyphenazine
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Figure 2.

Proton NMR of pyocyanin. Pyocyanin (10 mg) was dissolved in
chloroform and TMS was used as a standard.
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Chloroform
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concentrations used. This indicates that the suppression observed in Figure 3 can not be
attributed to LPS contamination.
Having ascertained that pyocyanin had a suppressive effect on humoral immunity,
and that this suppression was not associated with toxicity or endotoxin contamination, we
were interested in determining the kinetics of this suppressive effect. Specifically, does the
time at which pyocyanin is administered (i.e., before or after SRBC) alter the suppressive
effect. Mice were injected with pyocyanin (1.0 ^g), prior to, at the same time, or
subsequent to the i.v. injection of SRBCs. Four days later, control and experimental
animals were sacrificed, spleens removed, and the number of PFUs quantitated.
Data represented in Figure 4 illustrates that mice receiving pyocyanin before SRBCs
also exhibit a suppressive effect. Specifically, when pyocyanin was administered 12 h
prior to SRBCs, this resulted in an 83% suppression. This however was statistically
different from the 72% suppression observed when pyocyanin was administered 6 h prior
to SRBCs, but was not from animals who received pyocyanin at the same time as SRBCs
(78% suppression) (P <0.05). Interestingly, the data shown in Figure 5 illustrates that
pyocyanin administered 12 h subsequent to injection of SRBCs had the greatest
suppression at 79%. This was a dramatic difference in the number of PFUs from animals
receiving pyocyanin 6 h subsequent to SRBCs (41% suppression) and pyocyanin at the
same time as SRBCs (66 % suppression). These differences were also statistically
different (P <0.05) from each other. Overall, when pyocyanin is administered 12 h prior to
or subsequent to SRBCs, there appears to be a dramatic suppressive effect which is
statistically different from pyocyanin being administered at the same time as SRBCs or 6 h
prior to or subsequent to SRBCs. The observed suppression does not appear to be caused
by toxicity of pyocyanin.
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T h e e ffe c t o f p y o c y a n in on c y to k in e m R N A e x p r e ssio n

The mechanism of action of the observed suppressive effect of pyocyanin needed to
be investigated. One possibility was that pyocyanin had an effect on the ability of immune
cells to either produce and/or release cytokines which are necessary for the generation or
maintenance of a humoral immune response. To determine the effect, if any, of pyocyanin
on the expression of mRNA specific for cytokines, namely, IL-1, IL-4, IFN-y, and TNF,
animals were treated with media alone, SRBC alone, and pyocyanin 12 h prior to SRBC,
or pyocyanin and SRBC at the same time. Four days later, the spleens were removed, and
cells were enriched for each of the following groups: the unseparated population (US),
which consists of a mixture of APC’s, neutrophils, NK cells, B and T-lymphocytes: the
adherent cell population (A), which is primarily monocytes and macrophages; and the non
adherent cell population (NA), which is primarily T-lymphocytes and some NK cells. Total
RNA was isolated from each of the cell populations, and was reverse transcribed and the
cDNA amplified using PCR. Primers specific for each cytokine were used in the
amplification process. Signals representing the expression of RNA for IL-4 were not
apparent for any group of cells. Data in Figure 6 represents the expression of mRNA
specific for cytokines in the group of animals treated with media alone, SRBC alone, and
those animals treated with pyocyanin and SRBC at the same time. Panel A in Figure 6
represents animals that were treated with media alone. In panel A, bands appear for IFN-y
in both the US population and the A population (Figure 6). Panel B represents data from
animals treated with SRBC alone, which was the positive control. Panel B illustrates that
in the US population and the NA population, there are faint bands for IFN-y (Figure 6 ).
Panel C represents data from animals treated with pyocyanin and SRBC at the same time.
Panel C illustrates that there are faint bands visible in both the US and A populations for
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TN F, and bands for IFN-y also appear in both the US and NA populations (Figure 6).
Data in Figure 7 represents the expression o f m R N A specific for cytokines in the
group o f animals treated with media alone, SR BC alone, and those animals treated with
pyocyanin 12 h prior to SRBC. Panel A in Figure 7 represents animals that were treated
with media alone. Data in panel A demonstrates that there are bands specific for TN F
which appear in all three cell populations, U S, A , and N A (Figure 7). Panel B represents
data from animals treated with SRBC alone, which was the positive control. Data in panel
B , Figure 7, show s that there are very faint bands for IL-1 which appear in all three cell
populations, and there are also bands that appear for T N F in both the U S and A
populations. Panel C represents data from animals treated with pyocyanin 12 h prior to
SRBC. Data from panel C demonstrates that the only bands visible are for TNF, and these
bands appear in all cell populations (Figure 7).
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Figure 3.

The effect o f pyocyanin on the hem olytic plaque forming response when
injected simultaneously with antigen at different concentrations (1 .0 ,1 0 .0 ,
and 100.0 /<g). SRBC and pyocyanin were given at the same time (time 0),
and spleens were removed four days after treatment. The treatments were
as follow s: SRBC alone C

), Pyocyanin (1.0 /tg) ( □ ) , Pyocyanin

(10.0 /tg) ( E 23), and Pyocyanin (100.0 /tg) ( ES31 all at the same tim e as
SR BC. Each bar represents the mean (n = 6) plus or minus the standard
error o f the mean. Statistics include a single factor A nova in order to
compare differences between groups (P < 0.05).
* : indicates that there is a statistically significant difference to all groups
* * : indicates that there is a statistically significant difference between this group and
100.0 fig pyocyanin
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Table 1. The effect o f pyocyanin on the viability o f m ouse spleen cells3

Hours Post Injection

Normal^ (% Viable)

Experimental!, (% Viable)

2

96

9 4 .4

4

95

9 6 .8

6

95

87

12

94

87

24

96

88

aM ice received an intravenous injection o f either RPM I 1640 (normal) or 0.1 m l 10 /tg/m l pyocyanin (1.0
^g ) (experimental)
bPercent v ia b ility determined by Trypan Blue exclusion
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Table 2. The effect of pyocyanin on mouse spleen cells in a lymphocyte proliferation assay

G rou p

C o n c e n tr a tio n (/zg)a

C o u n ts p er m inuteb

150

Control
Con A

0.01

23,025 +/- 2000

LPS

0.1

14,001 +/- 3052

Pyocyanin

0.005

11 9 + /-4 9

0.01

137 +/- 48

0.05

129 +/- 40

0.1

73 +/- 19

1.0

87 +/- 36

aNormal mouse spleen cells were cultured at a concentration of 4x1 CP cells/well (100 /d) in the presence of
media alone, mitogen (Con A and/or LPS), or different concentrations of pyocyanin
bEach number represents the mean of 3 wells, replicated 3 times (n = 9).
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Figure 4.

The effect o f pyocyanin on the hem olytic plaque form ing response when
injected simultaneously and prior to antigen at the same concentration (1.0
/rg). M ice were treated with media alone, SR BC alone ( ) ,
h(I

pyocyanin 6

I) and 12 h ( EZ3) before SR BC , and pyocyanin at the same time

as SR BC ( E S 3). Each bar represents the mean (n = 6) plus or minus the
standard error o f the mean. Statistics include a single factor Anova in order
to compare differences between groups (P < 0.05).
*: indicates that there is a statistically significant difference to all groups
* * : indicates that there is a statistically significant difference between these two groups

38

PFL's per 10‘ cells

SRBC

39

before
SRBC

time as
SRBC

Figure 5.

The effect of pyocyanin on the hemolytic plaque forming response when
injected simultaneously and subsequent to antigen at the same
concentration (1.0 ^g). Mice were treated with media alone, SRBC alone
( W

), pyocyanin 6 h ( I

I ) and 12 h (

) after SRBC, and pyocyanin

at the same time as SRBC ( [W ). Spleens were removed from the mice 4
days

after treatment. Each bar represents the mean (n = 6) plus or minus

the standard error of the mean. Statistics include a single factor Anova in
order to compare differences between groups (P < 0.05).
*: indicates that there is a statistically significant difference to all groups
**: indicates that these groups are statistically different
¥: indicates that these groups are statistically different
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SRBC

41

PFU's per 10* cells

Figure 6.

The effect of pyocyanin on the expression of mRNA specific for IL-1,
TNF, and IFN-y when injected simultaneously with antigen. Mice were
injected with media alone, SRBC alone, and pyocyanin (1.0 ^g) at the same
time as SRBC. p-A ctin was used as the positive control for the PCR
reaction. The bands, which represent mRNA specific for a particular
cytokine, were compared visually on the basis of intensity.
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US

A

Panel C
SRBC + Pyocyanin at same time

Panel B
SRBC alone

Panel A
Media alone
NA

US

A

P-Actin
IL-1

TNF

IFN-y

US-Unseparated cell population
A-Adherent cell population
NA-Non-adherent cell population
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NA

US

A

NA

Figure 7.

The effect o f pyocyanin on the expression o f m R N A specific for IL-1,
T N F, and IFN-y when injected 12 h prior to antigen. M ice were
injected with media alone, SRBC alone, and pyocyanin (1.0 pig) 12 h prior
to SR BC. P -A ctin was used as the positive control for the PCR reaction.
The bands, which represent m RNA specific for a particular cytokine, were
compared visually on the basis o f intensity.
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Panel B
SRBC alone

Panel A
Media alone

US

A

NA

US

US-Unseparated cell population
A-Adherent cell population
NA-Non-adherent cell population
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A

Panel C
Pyocyanin 12h before SRBC

NA

US

A

NA

C H A P T E R IV
D IS C U S S IO N

The primary purpose of this research was to determine if pyocyanin, when given
intravenously, has an effect on the humoral immune response of mice. Once the effect of
pyocyanin on the humoral immune response of mice was established, studies were
designed to ascertain the kinetics of the response. Lastly, preliminary data was obtained
about the potential effect of pyocyanin on the expression of mRNA specific for certain
cytokines likely to be involved in regulating the development of a humoral immune
response.
Pyocyanin is the low molecular weight, blue pigment produced from actively
growing cultures of P. aeruginosa (4, 9-10). Pyocyanin has been demonstrated to have a
variety of effects on both eukaryotic and prokaryotic cells including: the inhibition of ciliary
beat function of respiratory epithelia, blocking of nitric oxide release and vasodilation in
smooth muscle cells, and the antimicrobial effect on certain gram positive bacteria (i.e.,
Staphylococci) ( 9-10, 34-35, 39, 77). For the purposes of this research, it was important
to examine the possible ways that pyocyanin disrupts normal cell function in order to
determine the effect of pyocyanin on the humoral immune response.
Kanthakumar et. al. (35), have identified several “ciliatoxins”, substances which
slow ciliary beat frequency and in some cases, can cause ciliary dyskinesia, a
disorganization of ciliary beat patterns. Two of the three toxins identified are pyocyanin
and it’s breakdown product, 1-hydroyphenazine. In studies conducted by Kanthakumar et.
al. (1996) (35), it was shown that the onset of the effect of pyocyanin on nasal ciliated
epithelium occurs before there is cell damage, and that the slowing of ciliary beat frequency
by pyocyanin is associated with a fall in the levels of both cAMP and ATP. This was
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especially important as previous studies have shown that cAMP is a regulator of ciliary'
activity (35). The mechanism of action of pyocyanin on epithelial cells appears to be a
reduction in the level of adenosine nucleotides, which in turn reduces the intracellular levels
of both cAMP and ATP (35). There are two possible explanations for the mechanism in
which pyocyanin and other ciliatoxins affecting epithelial cells can cause a decrease in
adenosine nucleotides. The first possibility is that the inhibition of oxidative
phosphorylation by toxins could reduce the amount of ATP which is available to generate
ciliary movement, which could then downregulate the production of intracellular cAMP
(35). Another possibility is that the toxins may be acting directly on the production of
cAMP intracellularly which could then affect the generation of ATP by the cell and the
utilization of ATP by the cilia (35). 1-Hydroxyphenazine, the breakdown product of
pyocyanin, which has a similar effect on cAMP, has been specifically identified at
poisoning the electron transport chain within the mitochondria (35). This was interesting as
in a previous study conducted by Miller et. al. (1987) (45), it was determined that
pyocyanin inhibited the uptake of molecular oxygen by mouse monocytes among other
cells, and the mechanism of action was that pyocyanin decreased cellular respiration by
inhibiting electron transport, specifically at the ubiquinone-cytochrome b site in the electron
transport chain (5, 9-10). The mitochondrial outer membrane is permeable to all molecules
that are 10,000 daltons or less, which both pyocyanin and 1-hydroxyphenazine are,
however, the inner membrane, which houses the electron transport chain is generally
impermeable to molecules of this size (68). Somehow, however, pyocyanin is able to
penetrate the inner membrane and disrupt electron transport, which makes it feasible that
this pigment can potentially penetrate other cellular membranes as well. These findings are
important as they provide clues as to the effect of pyocyanin intracellularly.
As previously mentioned, pyocyanin has also been associated with the inhibition of
nitric oxide release by and subsequent vasorelaxation by smooth muscle cells (77). The
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exact mechanism of action by which pyocyanin interacts with nitric oxide is not known,
however there is one possible explanation. In previous studies, it was found that when
nitric oxide was passed through a deoxygenated aqueous solution of pyocyanin, a color
change occurred from the usual blue color, at neutral pH, to pink, indicative of an acidic
pH (77). Mass spectroscopy revealed that the pyocyanin had completely disappeared, and
only small amounts of 1-hydroxyphenazine and 1-methoxyphenazine, and two larger ions
had remained (77). It was speculated that these two larger ions could have been formed
due to the nitrosylation of pyocyanin by nitric oxide (77). This study suggests that a
reaction between pyocyanin and nitric oxide may also occur in vivo, being a possible
explanation for the inhibition of nitric oxide release and subsequent vasodilation (77).
The structural analysis of pyocyanin (Figure 1) may also provide some insight into
the mechanism of action of this pigment on cell function. Pyocyanin, a zwitterionic
compound, is an electron acceptor and carrier and has the capability of being reduced in an
aqueous system (68). In addition, the low molecular weight of pyocyanin (210 daltons)
suggest that although not likely to be immunogenic, it may be able to pass through cell
membranes with relative ease. Although the biological effects of this compound have not
been characterized, some possible effects based upon the chemical structure could include
the ability to first attract an electron from a substrate, and then later donate the electron to an
acceptor such as oxygen (68). In this scenario, the formation of toxic oxygen radicals
could potentially alter important cellular functions thus resulting in tissue destruction and
possible immune disruption (68). The possibility that pyocyanin has an effect on immune
cell functioning, thereby providing a selective advantage to Pseudomonas aeruginosa in
colonization of the lung is the primary reasoning behind this research.
Immunoglobulins, released by B-lymphocytes upon antigenic stimulation, are the
major glycoproteins of the humoral immune system (56). The hemolytic plaque assay is an
indirect method for measuring whether or not immunoglobulins are being produced in
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response to SRBC, an antigen. This assay is a useful tool tor measuring whether or not
particular products, which are not mitogenic or antigenic alone, could influence the ability
of a host to produce antibodies to a known antigen. This assay was used to measure the
effect of pyocyanin on the ability of mice to produce immunoglobulins to SRBC. Initially,
pyocyanin was injected into mice at different concentrations (1.0, 10.0, and 100.0 /zg)
simultaneously with SRBCs. Pyocyanin at the 1.0 /zg concentration proved to have the
greatest suppression of PFUs at a 74% reduction as compared with mice injected with
SRBC only (Figure 3). This dramatic decrease in the number of PFUs suggested that
pyocyanin had a definite suppressive effect on the humoral immune response. Further
experimentation was needed to ascertain the kinetics of this effect. Therefore, it was
decided that pyocyanin at this concentration would be used for all subsequent
experimentation. The viability of mouse splenocytes appeared not to be affected by the
injection of pyocyanin (1.0 /zg) when compared to mice injected with RPMI-1640 media
alone (Table 1). The percentage of viable splenocytes from mice injected with pyocyanin
did not fall below 87%. This finding ruled out the possibility that pyocyanin is toxic to
cells in vivo and any decline in the number of PFUs in the hemolytic plaque assay was
unlikely to be caused by cell death as a result of direct toxicity of the pigment.
Next, pyocyanin (1.0 /zg) was injected into mice 6 and 12 h prior, at the same time
as, and 6 and 12 h subsequent to SRBC. Pyocyanin injected 12 h prior to SRBC resulted
in an 83% reduction in the number of PFUs when compared with the number of PFUs
from animals who received SRBC only (Figure 4). This reduction was statistically
different (P <0.05) from the percent reduction of PFUs obtained from animals injected with
the pigment 6 h prior to SRBC (72%), but not from those who received pyocyanin at the
same time as SRBC (78%) (Figure 4). What was even more interesting was that when
pyocyanin was administered 12 h subsequent to injection with SRBCs, the percent
reduction was again dramatic at 79%, and also statistically different (P < 0.05) from
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pyocyanin 6 h subsequent to or at the same time as SRBC (Figure 5). These kinetic studies
indicate that pyocyanin has the greatest suppressive effect on the humoral immune response
when administered either 12 h prior or subsequent to SRBC. However, the bottom line is
that pyocyanin (1.0 /rg), when administered prior, at the same time as, or subsequent to
SRBC results in dramatic suppression of PFUs as measured by the hemolytic plaque
assay. This suggests that pyocyanin was interfering with the ability of animals to mount a
humoral immune response, although the mechanism of action was unclear.
The effect of pyocyanin on the cells primarily involved in the humoral immune
system has not been widely characterized, however there is some data that may indicate the
mechanism of action of this pigment on these cells. In addition to inhibiting lymphocyte
proliferation, pyocyanin has also been implicated in influencing superoxide anion
production by neutrophils (9-10, 68-69). However, at lower concentrations of the pigment
(less than 5 /<M), superoxide production has been shown to be enhanced, thus amplifying
tissue destruction (68-69). This dose-dependent phenomenon has also been shown with
monocytes and macrophages, that in the presence of certain concentrations of pyocyanin,
phagocytosis has actually been enhanced by these cells (49). Conversely, because of the
nature of the chemical structure of pyocyanin, being an electron acceptor, it is theorized that
perhaps it interferes with the oxidative burst of phagocytes, which is important for
antimicrobial defense in vivo (49). However, this does not provide a substantial
explanation for the suppression of plaque forming cells observed during this research.
There are two possibilities for the observed data presented; first, a combined effect was
taking place. Perhaps there was cellular damage resulting from superoxide production by
neutrophils. Possibly, certain immune cells were also not functioning properly due to the
interference of electron transport and cellular respiration. Perhaps many cells died in the
process, thus lowering the overall number of plaque forming units, but this is not likely
given the cell viability data (Table 1). Secondly, the fact that B-cell responses to SRBC are
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controlled by several different factors, including the cytokines IL-1 and IL-2, points to an
alternative possibility for our observations (43). In studies conducted by Marrack et. al.
(43), it was shown that in order to generate an anti-SRBC response resulting in PFUs, it
was necessary for certain substances to be present in the media that would act on B-cells to
induce this response. In addition, the production of antibodies is dependent on the
interaction between B and T- lymphocytes (3). B-cells alone could not induce an antiSRBC response (43). With this in mind, it was decided that the effect was probably taking
place at the molecular level, which could possibly explain the general suppression of
PFUs, namely by the involvement of cytokines.
Certain cytokines have important immune functions through the induction of cell
activation, growth, and differentiation (2, 12, 48, 62). IL-1 is an important cytokine
involved in B-cell activation, and recently, it was demonstrated that IL-1 was an important
component in the process by which PFUs are formed in response to SRBC (3). Previous
studies have demonstrated that the addition of anti-IL-1 neutralizing antisera to activated Bcells in the presence of Staphylococcus aureus Cowan and IL-2, suppressed the formation
of immunoglobulin-secreting cells (3). It is possible that pyocyanin inhibits the release of
IL-1, thereby resulting in a suppression of PFUs in response to SRBC. Studies have also
shown that IFN-y works in synergy with both IL-1 and IL-2 in response to SRBC in vitro
(3). If the mechanism of action of pyocyanin was on IFN-y, then the effect of this
pigment was probably additive, therefore affecting the synergistic relationship of different
cytokines. Although not studied directly, IL-2 is another cytokine of interest potentially
involved in the humoral immune response. IL-2, once thought to act specifically on Tcells, was later found to exert several actions on other cell types, especially B-cells (3).
Not only does IL-2 induce the proliferation of B-lymphocytes, but it also induces the
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secretion of immunoglobulins from activated B-cells (3). IL-4 is yet another cytokine that
stimulates the proliferation and differentiation of B-lymphocytes and the subsequent release
of immunoglobulins as well (3). In bacterial infections, the production of TN F-a and IL-1
by immune cells is induced by gram negative bacterial endotoxins, and for this reason,
these cytokines may somehow mediate certain aspects of gram negative bacterial
pathogenesis (54). IFN-y has also been shown to activate macrophages and monocytes in
vitro and in vivo, and it may also play an important role in the destruction of intracellular
pathogens (54). Inactivation of cytokines such as IFN-y, TN F-a and IL-1, could lead to
the inability of a host to mount an immune response to gram negative bacterial pathogens,
such as Pseudomonas aeruginosa . This was the rationale for collecting data on the effect
of pyocyanin on certain cytokines potentially involved in the humoral immune response,
namely IFN-y, T N F -a and IL-1.
Parmely et al. (1990) examined the proteolytic inactivation of IFN-y, TN F-a and IL1 by Pseudomonas aeruginosa alkaline protease and elastase, however there has not been
any research conducted on the inactivation of cytokines by other Pseudomonas products,
namely pyocyanin (54). As mentioned previously, inactivation of IFN-y , T N F -a and IL1 could lead to significant reduction in the antiviral and general immunomodulatory
activities (54). The suppressive effect of pyocyanin on humoral immunity, which was not
caused by cell death from toxicity or LPS contamination, lead to further exploration of the
mechanism of action of suppression by the phenazine pigment. There are two possible
ways, among many, to explore the mechanism of action of pyocyanin on the humoral
immune response. The first is to investigate the effect of pyocyanin on message specific
for those cytokines involved in the humoral immune response. The second is to determine
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the direct effect of pyocyanin on the biological activity of any or all immune cells (for
example, does pyocyanin affect the antigen presenting ability of monocytes, macrophages,
or B-cells). Because cytokines are such an integral part of induction of humoral immune
responsiveness, we decided to investigate whether or not the suppressive effect caused by
pyocyanin was due to the effect of this phenazine pigment on cytokine production.
In order to address the effect on cytokine production, it was necessary to examine
purified cell populations. Spleens taken from mice that were treated with pyocyanin (1.0
/zg) prior, at the same time as, and subsequent to SRBCs were removed and enriched tor
the following cell populations: unseparated population, the adherent mononuclear cell
population, and non-adherent cell population. The unseparated population contained a
mixture of A PC’s, neutrophils, B and T-lymphocytes, while the adherent cell population
was primarily monocytes and macrophages, and the non-adherent cell population was
primarily T-lymphocytes. Once the desired cell populations were obtained, total RNA was
isolated, reverse-transcribed, and cDNA amplified by PCR to detect signals specific for the
cytokines investigated.
The cytokines investigated include IL-1, IL-4, IFN-y, because they are all cytokines
which in some way affect cells involved in the humoral immune response (macrophages, B
and T-lymphocytes) through either activation or promotion of cytokine secretion (2).
Signals representing the expression of RNA for IL^I were not apparent for any of the
enriched cell populations (Figures 6 and 7). The trend for the signals for IL-1 in all
enriched cell populations in mice that received SRBC only as well as any of the treatment
groups appeared to be very faint or non-existent (Figures 6 and 7). IL-1 is generally
produced by monocytes and macrophages and promotes T-lymphocyte proliferation (2,
21). Therefore, in normal unseparated populations of cells, one would expect that signals
for IL-1 be detected. Signals for TNF were particularly bright in the unseparated and
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adherent cell populations in mice receiving SRBCs only, pyocyanin 12 h prior to SRBC,
and also pyocyanin and SRBC at the same time (Figures 6 and 7). TNF should be detected
because it is also produced by monocytes (2). The signals for IFN-y were similar to those
for IL-1, with the exception of bright bands which appeared in the unseparated and nonadherent cell populations when pyocyanin and SRBC were given at the same time (Figure
6).
In the unseparated population of cells from mice treated with media alone, signals
for the expression of IL-1 and TNF are extremely faint, while the signal for IFN-y was
slightly stronger (Figure 6). The signals for IL-1 and TNF would have been expected to be
a little brighter as in Figure 7, while the expression of IFN-y was not expected at all, since
media alone does not constitute any mitogenic or antigenic stimulation (Figure 6). The
bands for IL-1 and TNF in the adherent populations would also be expected to have been
brighter, since the adherent population consists of primarily monocytes and macrophages
(Figure 6). Again, there should not have been a signal for IFN-y. There were no signals
detected in the normal, non-adherent cell population which was as expected (Figure 6). A
possible explanation for this is that pyocyanin alone is not immunogenic. It does not
contain any mitogenic properties nor was it secreted by a bacterial cell in vivo. Conversely,
LPS from gram negative bacterial cells stimulates the release of IL-1 and TN F-a (21, 62).
In the group of animals treated with SRBC alone (Figure 6), one would expect that the
signals for each cytokine (IL-1, TN F-a, and IFN-y) should very bright when compared to
the bands which appeared in the group that received media alone due to the fact that SRBCs
are antigenic and therefore have a stimulatory effect on mouse splenocytes. A possible
explanation for this is perhaps human error in the injection procedure of these animals, or
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more likely, the RNA levels isolated were too low to be detected. However, without
accurate representation from the positive control group (SRBC), one cannot draw any
definite conclusions about the animals that were injected with SRBC and pyocyanin (1.0
/ig) at the same time.
Figure 7 demonstrates that the group of animals treated with pyocyanin (1.0 /zg) 12 h
before SRBC, mediates decreased signals for each of the cytokines in each cell population
as compared to SRBC alone, with the exception of T N F-a, which exhibited a strong signal
in the non-adherent population of experimental animals. This indicates that perhaps
pyocyanin is indeed suppressing cytokines necessary for an anti-SRBC response, namely
those which act upon B-lymphocytes. However, again, due to the fact that the RNA
results obtained in the control groups were not consistent with the literature or previous
research, then a conclusive explanation cannot be drawn.
In order to ascertain whether or not message specific for key cytokines was expressed
from enriched cell populations, i.e., macrophages, B cells or T cells, it is critical that pure
populations of cells be used in the isolation of RNA. The techniques used in the
preliminary study presented, involving either plastic adherence or Percoll gradients, allows
for the enrichment of cells, such as monocytes and T lymphocytes. However, one must
remember that these in no way represent pure cell populations. It is possible that some of
the conflicting data presented could be accounted for by contaminating cells remaining in a
specific highly “enriched” cell population. To avoid this problem in the future would
require the use of a flourescence activated cell sorter (FACS) and monoclonal antibodies
specific for each cell population. Ideally, FACS analysis would avoid some of the pitfalls
previously mentioned, and would better answer the question as to whether pyocyanin
diminishes the expression of key cytokines involved in the development of a humoral
immune response.
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An alternative approach to determining the mechanism of suppression observed with
pyocyanin would be to evaluate the direct effect of this phenazine compound on normal
function of key cell populations. For example, is it possible that pyocyanin, produced
during an ongoing infection, might adversely affect the ability of macrophages to process
and present antigen to T and B cells? Alternatively, could pyocyanin inhibit the
differentiation and proliferation of mature B cells to antibody producing plasma cells?
Similar to answering the cytokine question, this approach would require “pure” cell
populations. The approach taken would involve obtaining spleen cells from normal mice,
and isolating each specific cell type using FACS anaylsis. Having obtained a pure
population, i.e., macrophages, these cells would then be cultured in the presence or
absence of different concentrations of pyocyanin for vaiying time periods. Repeat this for
each cell type being studied. These “treated” cell populations would then be co-cultured
with the remaining two untreated cell populations. To these cell cultures, one would add
antigen (S-RBCs) and incubate for four days. Following incubation, a standard hemolytic
plaque assay would be performed. The total number of PFUs for each set of cultures
would be quantitated, and compared to control values. If treatment of a specific cell
population resulted in a reduced number of plaques, this would support the hypothesis that
this compound directly inhibits normal cell function, thereby resulting in suppression of a
normal immune response.
As an opportunistic pathogen, Pseudomonas aeruginosa is a major threat to those
individuals whose immune system is compromised, including bum and cancer patients, as
well as cystic fibrosis children. It has previously been reported that this organism is
capable of producing numerous virulence factors, many of which may play a key role in the
genesis of disease. This study illustrates that pyocyanin, a water soluble pigment, has a
significant suppressive effect on the development of a humoral immune response. What is
unclear is the exact mechanism involved in the observed suppression. Although
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preliminary in nature, data presented raises the possiblity that one explanation might
involve inhibiting the expression of messenger RNA specific for the synthesis of key
cytokines, i.e., IL-1, T N F -a or IL-6. Although not immunogenic, pyocyanin appears to
be involved in the pathogenesis of disease caused by this organism, and warrants future
investigation. In particular, it would be important to ascertain whether pyocyanin affects
both arms of the immune system, i.e., humoral as well as cellular immunity. A
suppressive effect on T cell function could alter cytotoxic activity of T cells and
macrophages, thereby increasing the incidence of cancer or infectious disease.
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